Current open trials in Cambridge
Please download a list of current open trials for renal cancer coordinated by the Cambridge Cancer Trials Centre (last updated January 2016).
|Trial name||Trial description||Contact|
|A-PREDICT||A-PREDICT - A Phase II Study of Axitinib in Patients with Metastatic Renal Cell Cancer Unsuitable for Nephrectomy||Prof Tim Eisen|
|Pazopanib in patients with renal cancer (PaZ02)||A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and ECOG Performance Status 2 (PaZ02)||Dr Kate Fife|
|STAR Standard vs Modified Drug Therapy in Renal Cancer||STAR: A randomised multiStage phase II/III trial of Standard first-line therapy (sunitinib or pazopanib) comparing Temporary cessation with Allowing continuation, at the time of maximal radiological response, in the firstline treatment of locally advanced and/or metastatic Renal cancer||Prof Tim Eisen|
|WO29637 - MPDL3280A in renal cell||A phase III, open-label, randomized study of MPDL3280A (Anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma||Dr Kate Fife|
If you would like further information about how to take part in any of the clinical trials listed here that are open to recruitment, please talk to your cancer specialist as patients usually need to be referred by their doctor.